№2025-059 変更
2025年9月

報告書変更のお知らせ

謹啓　時下ますますご清栄のこととお慶び申し上げます。
平素は格別のご高配を賜り厚くお礼申し上げます。
この度、下記検査項目におきまして、報告書の変更をご案内いたします。
健康と医療の未来に貢献すべく、より良い検査サービスのご提供に努めてまいります。
謹白

記

■ 対象項目・変更日

項目コード（旧項目コード）	検査項目	変更日
02690 3（2690 5）	BRCA1/2遺伝子検査（乳癌）	2025年10月2日 ダウンロード分より
0R221 8（R221 7）	BRCA1/2遺伝子検査（卵巣癌）	
0R638 6（R638 8）	BRCA1/2遺伝子検査（HBOC）	
0U052 3（U052 0）	BRCA1/2遺伝子検査（膵癌）	
0R629 6（R629 0）	BRCA1/2遺伝子検査（前立腺癌）	
0R615 1（R615 5）	BRCA1/2遺伝子シングルサイト検査	2025年8月17日　21:50 ダウンロード分より

■ 変更内容・概要

米国Myriad社のシステムよりダウンロードいただいている報告書の中の、Patient Copy（通常報告書の１枚目のMyriad担当者のサインがないもの）を削除いたします。

■ 対応方法

Patient Copyが必要な場合は、対象の報告書をコピーもしくは２部出力いただき、ご対応のほど、お願い申し上げます。

SRL Communication for Health
データインフォメーション　TEL: 03-6837-6344
https://www.srl-group.co.jp/

■ 変更点についての詳細

対象項目においては、医療機関用とPatient Copy（通常報告書の１枚目のMyriad担当者のサインがないもの）を報告しておりました。
変更日以降は、Patient Copyを削除いたします。医療機関用とPatient Copyの相違点はMyriad社担当者のサインの有無及びのみで、報告内容は同一です。

■ 医療機関用報告書とPatient Copyの相違点

下記の赤枠部分のMyriad社担当者のサインのみが異なります。
その他の部分は同一です。

医療機関用報告書


CONFIDENTIAL

BRACAnalysis診断システム®

BRCA1 and *BRCA2* Analysis Result

Myriad genetics

RECEIVING HEALTHCARE PROVIDER

SPECIMEN
Specimen Type: Blood
Draw Date: May 27, 2025
Accession Date: May 29, 2025
Report Date: Jun 05, 2025

PATIENT
Legal Name:
Date of Birth:
Patient ID: 527-6Z48-9035
Sex at Birth: F
Accession #: 05428568-BLD
Requisition #:

GENETIC RESULT: NEGATIVE - NO CLINICALLY S MUTATION ID
At this time, any genetic changes identified in this report are not known to warrant modificati
medical management beyond what is indicated by the patient's personal and family history.

TREATMENT IMPLICATIONS

Patients with breast, ovarian, pancreatic, or prostate cancer who do not have deleterious or suspected deleterious germline *BRCA1* or *BRCA2* mutations may not be eligible for treatment with Lynparza® (olaparib). Patients with breast cancer who do not have deleterious or suspected deleterious germline *BRCA1* or *BRCA2* mutations may not be eligible for treatment with Talzenna® (talazoparib tosilate).

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

ADDITIONAL INFORMATION

Genes Analyzed: Unless otherwise noted sequencing and large rearrangement analyses were performed on the following genes: *BRCA1, BRCA2*

Intended Use: This device is used as an aid for detecting germline *BRCA1* or *BRCA2* gene mutations in genomic DNA extracted from whole blood and for determining the eligibility of patients with breast, ovarian, pancreatic, or prostate cancer for olaparib treatment or patients with breast cancer for talazoparib tosilate treatment.
This device is also used to identify individuals with a high risk of *BRCA*-Related Breast and/or Ovarian Cancer (HBOC) Syndrome and may be used as an aid for informing medical management decisions.

The majority of deleterious or suspected deleterious mutations identified by Myriad in *BRCA1* and *BRCA2* are classified using objective criteria based on the type and genomic position of the variants. Other deleterious or suspected deleterious mutations may be classified by other criteria that are based on available evidence. The classification and interpretation of all variants identified in this assay reflect the current state of Myriad's scientific understanding at the time this report was issued. Variant classification and interpretation may change for a variety of reasons, including but not limited to, improvements to classification techniques, availability of additional scientific information, and observation of a variant in more patients. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported. If you have questions or concerns about how the variant(s) in this result report was classified, please contact customer support.

ご不明な点がございましたら、エスアールエル データインフォメーションへお問合せください。
TEL.03-6837-6344（医療機関専用問い合わせ先）

Laboratory Director

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these results should be evaluated with regard to the cancer genetic risks for the patient and potentially for other family members.

Myriad genetics

Genetic Result
Page 1 of 2

Patient Copy（削除対象）


PATIENT COPY CONFIDENTIAL

BRACAnalysis診断システム®

BRCA1 and *BRCA2* Analysis Result

Myriad genetics

RECEIVING HEALTHCARE PROVIDER

SPECIMEN
Specimen Type:
Draw Date:
Accession Date
Report Date:

PATIENT
Legal Name:
Date of Birth:
Patient ID:
Sex at Birth:
Accession #:
Requisition #:

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
At this time, any genetic changes identified in this report are not known to warrant modification of the patient's medical management beyond what is indicated by the patient's personal and family history.

TREATMENT IMPLICATIONS

Patients with breast, ovarian, pancreatic, or prostate cancer who do not have deleterious or suspected deleterious germline *BRCA1* or *BRCA2* mutations may not be eligible for treatment with Lynparza® (olaparib). Patients with breast cancer who do not have deleterious or suspected deleterious germline *BRCA1* or *BRCA2* mutations may not be eligible for treatment with Talzenna® (talazoparib tosilate).

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

ADDITIONAL INFORMATION

Genes Analyzed: Unless otherwise noted sequencing and large rearrangement analyses were performed on the following genes: *BRCA1, BRCA2*

Intended Use: This device is used as an aid for detecting germline *BRCA1* or *BRCA2* gene mutations in genomic DNA extracted from whole blood and for determining the eligibility of patients with breast, ovarian, pancreatic, or prostate cancer for olaparib treatment or patients with breast cancer for talazoparib tosilate treatment.
This device is also used to identify individuals with a high risk of *BRCA*-Related Breast and/or Ovarian Cancer (HBOC) Syndrome and may be used as an aid for informing medical management decisions.

The majority of deleterious or suspected deleterious mutations identified by Myriad in *BRCA1* and *BRCA2* are classified using objective criteria based on the type and genomic position of the variants. Other deleterious or suspected deleterious mutations may be classified by other criteria that are based on available evidence. The classification and interpretation of all variants identified in this assay reflect the current state of Myriad's scientific understanding at the time this report was issued. Variant classification and interpretation may change for a variety of reasons, including but not limited to, improvements to classification techniques, availability of additional scientific information, and observation of a variant in more patients. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported. If you have questions or concerns about how the variant(s) in this result report was classified, please contact customer support.

ご不明な点がございましたら、エスアールエル データインフォメーションへお問合せください。
TEL.03-6837-6344（医療機関専用問い合わせ先）

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these results should be evaluated with regard to the cancer genetic risks for the patient and potentially for other family members.

Myriad genetics

Genetic Result
Page 1 of 2